NNVCNanoViricides, Inc.
1.665USD-5.93%Mkt Cap: 37.93M USDP/E: Last update: 2026-06-01

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for…

Indicators:|

Key Statistics

Company
Market Cap37.93M USD
Enterprise Value37.05M USD
Revenue (TTM)
Gross Profit
Net Income (TTM)-9.47M USD
Revenue/Share
Last Price1.665 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6300873022
Valuation
P/E (Trailing)
P/E (Forward)-5.09
PEG
EV/EBITDA-4.86
EV/Revenue
P/S
P/B3.47
EPS (TTM)-0.44
EPS (Forward)-0.35
52W Range
0.850059% of range2.230
52W High2.230 USD
52W Low0.8500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-125.93%
ROA-107.29%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-8.48M USD
CapEx (TTM)56.96K USD
FCF Margin
FCF Yield-11.58%
Net Debt-3.21M USD
Net Debt/EBITDA0.42
Balance Sheet
Debt/Equity
Current Ratio3.17
Quick Ratio3.02
Book Value/Sh0.5130 USD
Cash/Share0.1480 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay DateSep 24, 2019
Splits
Last Split1:20
Split DateSep 24, 2019
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)6.000 USD
Target Range6.000 USD6.000 USD
# Analysts1
Ownership
Shares Out.22.78M
Float21.08M
Insiders2.64%
Institutions8.34%
Short Interest
Short Ratio1.9d
Short % Float3.34%
Short % Out.3.24%
Shares Short702.02K
Short (prev mo.)731.85K
Technical
SMA 501.273 (+30.8%)
SMA 2001.290 (+29.0%)
Beta1.54
S&P 52W Chg27.94%
Avg Vol (30d)1.51M
Avg Vol (10d)3.79M
Technical Indicators
RSI (14)61.0
MACD0.1261
MACD Signal0.1147
MACD Hist.+0.0114
BB Upper1.852 USD
BB Middle1.571 USD
BB Lower1.291 USD
BB Width35.68%
ATR (14)0.1735 USD
Vol Ratio (20d)0.50x